The European Commission (EC) is proposing to adjust intellectual property (IP) rules to help Europe's pharma companies tap into fast-growing global markets.
Amgen and Allergan’s biosimilar of Roche’s cancer blockbuster Avastin has been approved in the EU, but there could be a four-year wait before the drug makes it to the market.
